Beneficial effect of cisplatin based combination chemotherapy on adenocarcinoma of the lung |
| |
| Authors: | H Ueoka T Ohnoshi T Numata S Kawahara K Nishii T Yonei H Yamashita J Ishii T Moritaka K Kiura |
| |
| Institution: | Second Dept. of Internal Medicine, Okayama University Medical School. |
| |
| Abstract: | Cisplatin (CDDP) based combination chemotherapy has improved the response rate of non-small cell lung cancer (NSCLC). However, the survival benefit of CDDP-based chemotherapy in patients with NSCLC is still controversial. In order to determine whether CDDP had a meaningful impact on the course of NSCLC, the survival of patients treated by combination chemotherapy containing CDDP (CDDP arm: PVB; CDDP + vindesine + bleomycin, VIP; vindesine + ifosfamide + CDDP) was compared with that treated by chemotherapy without CDDP (no CDDP arm: COMP; cyclophosphamide + vincristine + methotrexate + procarbazine, MVB; mitomycin C + vindesine + bleomycin), retrospectively. Survival in CDDP arm (median survival time MST]; 10.2 months) was significantly longer than in the no-CDDP arm (MST; 6.9 months) (p less than 0.01). These results indicate that CDDP-based combination chemotherapy can not only improve response rate but also prolong survival of NSCLC. |
| |
| Keywords: | |
|
|
